Mucosal Immunity, Vaccination & Biotherapies Laboratory, INSERM U1111-CNRS UMR5308, Université Claude Bernard Lyon 1, Ecole Normale Superieure de Lyon, Lyon, France.
INRA, UMR1319 Commensal and Probiotics-Host Interactions Laboratory, Micalis Institute, Jouy-en-Josas, France.
J Allergy Clin Immunol. 2018 Jan;141(1):163-170. doi: 10.1016/j.jaci.2017.02.022. Epub 2017 Mar 22.
Induction of oral tolerance to haptens is an efficient way to prevent allergic contact dermatitis (ACD) in mice. Toll-like receptor (TLR)-mediated sensing of the microbiota contributes to gut homeostasis, yet whether it contributes to induction of oral tolerance has not been documented.
We examined whether oral tolerance to the contact sensitizer 2,4-dinitro-fluorobenzene (DNFB) depends on microbiota/TLRs and evaluated the role of TLR4 on the tolerogenic function of intestinal dendritic cells (DCs).
Oral tolerance was induced by DNFB gavage in germ-free and mice deficient in several TLRs. Tolerance was assessed by means of suppression of contact hypersensitivity and hapten-specific IFN-γ-producing effector T cells. The tolerogenic function of intestinal DCs was tested by adoptive transfer experiments, ex vivo hapten presentation, and forkhead box p3 regulatory T-cell conversion.
Oral tolerance induced by DNFB gavage was impaired in germ-free mice and TLR4-deficient mice. Bone marrow chimeras revealed that TLR4 expression on hematopoietic cells was necessary for oral tolerance induction. TLR4 appeared to be essential for the ability of intestinal dendritic cells from DNFB-fed mice to inhibit ACD on adoptive transfer. Indeed, TLR4 conditioned the in vivo mobilization to mesenteric lymph nodes of intestinal migratory CD103 DCs carrying oral DNFB, especially the CD103CD11b DC subset expressing the vitamin A-converting enzyme retinaldehyde dehydrogenase and specialized in forkhead box p3-positive regulatory T-cell conversion.
Our data demonstrate that TLR4 conditions induction of oral tolerance to DNFB through licensing tolerogenic gut DCs. Oral biotherapy with TLR4 ligands might be useful to potentiate oral tolerance to haptens and alleviate ACD in human subjects.
诱导半抗原的口服耐受是预防小鼠变应性接触性皮炎(ACD)的有效方法。Toll 样受体(TLR)介导的微生物群感应有助于肠道内稳态,但它是否有助于诱导口服耐受尚未得到证实。
我们研究了变应原 2,4-二硝基氟苯(DNFB)的口服耐受是否依赖于微生物群/TLR,并评估了 TLR4 对肠道树突状细胞(DC)的耐受功能的作用。
通过 DNFB 灌胃诱导无菌和几种 TLR 缺陷小鼠的口服耐受。通过抑制接触超敏反应和半抗原特异性 IFN-γ产生的效应 T 细胞来评估耐受。通过过继转移实验、体外半抗原呈递和叉头框 p3 调节性 T 细胞转化来测试肠道 DC 的耐受功能。
DNFB 灌胃诱导的口服耐受在无菌小鼠和 TLR4 缺陷小鼠中受损。骨髓嵌合体显示 TLR4 在造血细胞上的表达对于口服耐受诱导是必需的。TLR4 似乎对于来自 DNFB 喂养小鼠的肠道树突状细胞抑制 ACD 的过继转移能力是必需的。事实上,TLR4 调节了携带口服 DNFB 的肠道迁移性 CD103 DC 向肠系膜淋巴结的体内动员,特别是表达维生素 A 转化酶视黄醛脱氢酶并专门用于叉头框 p3 阳性调节性 T 细胞转化的 CD103CD11b DC 亚群。
我们的数据表明,TLR4 通过许可耐受肠道 DC 来调节对 DNFB 的口服耐受诱导。TLR4 配体的口服生物疗法可能有助于增强对半抗原的口服耐受并减轻人类 ACD。